Disease/Infection News

RSS

Many states still lack the 21st century technology capacity needed for disease surveillance

Today, CDC's Morbidity and Mortality Weekly Report (MMWR) released a report showing that the number of state-level epidemiologists has decreased steadily since 2004, with a marked decline of over 10% since 2006.

18 Dec 2009

Government not held accountable for keeping nurses safe during SARS, Supreme Court denies appeal

Registered nurses in Ontario are devastated today to learn that the Supreme Court of Canada has denied an appeal of an earlier legal decision regarding responsibility for keeping nurses safe during the SARS outbreak.

18 Dec 2009

Human protein may help prevent H1N1 infection

Howard Hughes Medical Institute researchers have identified a naturally occurring human protein that helps prevent infection by H1N1 influenza and other viruses, including West Nile and dengue virus.

18 Dec 2009

AHF praises California Assembly members' initiative to protect state’s AIDS drug program funding

AIDS Healthcare Foundation (AHF) today praised the action taken by thirty-eight members of the California Assembly who, in a signed letter, urged Governor Schwarzenegger to protect funding for California’s AIDS Drug Assistance Program (ADAP). The Governor, who is currently completing his 2010-11 budget, could propose up to $70 million in cuts to ADAP in his upcoming budget, a move which, if enacted, will gut the state’s lifesaving AIDS drug program currently serving more than 35,000 low-income Californians living with HIV/AIDS.

18 Dec 2009

Immuno Laboratories and TRPN sign agreement to reduce chronic illness

Immuno Laboratories, a leading provider of food and environmental allergy testing services, announced an agreement with Three Rivers Provider Network (TRPN), the largest and fastest growing proprietary Preferred Provider Organization (PPO) network in the United States.

18 Dec 2009

New WHO report shows considerable progress in malaria

According to the World Health organization’s World Malaria Report 2009 released earlier this week, more than one third of affected countries included in the study have witnessed reduction in malaria cases by more than 50 percent between 2000 and 2008.

18 Dec 2009

Bill & Melinda Gates Foundation grants funds for visceral leishmaniasis research

The Hebrew University of Jerusalem Kuvin Center for the Study of Infectious and Tropical Diseases has received a $5 million grant from the Bill & Melinda Gates Foundation for research into visceral leishmaniasis.

18 Dec 2009

Genetic variant associated with reduced risk of COPD

What: Researchers have discovered evidence that suggests a genetic variant may be associated with better preserved lung function among children with asthma and adults who smoke, according to a new study funded by the National Heart, Lung, and Blood Institute (NHLBI), which is part of the National Institutes of Health.

18 Dec 2009

Flu-fighting proteins found in human cells stop flu virus, uncover scientists

In findings that may lead to better ways to prevent and treat influenza and other viral infections, researchers report the discovery of a family of naturally occurring antiviral agents in human cells.

18 Dec 2009

Comprehensive approaches to understand the interaction of H1N1 strains with human cells

Scientists have generated hundreds of new leads in the fight against the H1N1 flu pandemic, according to two new studies published online December 17th in the journal Cell, a Cell Press publication.

18 Dec 2009

Hebrew University of Jerusalem receives $5 million grant from Bill & Melinda Gates Foundation

17 Dec 2009

Update on Phase 2 clinical trial of oral interferon announced by Amarillo Biosciences

Amarillo Biosciences, Inc. (ABI) today announced that its ongoing study of oral interferon as prevention/treatment of influenza and other respiratory illnesses in Perth, Australia is nearing completion.

17 Dec 2009

La Jolla Institute for Allergy & Immunology awarded $18.8M NIH grant for infectious diseases study

Researchers from the La Jolla Institute for Allergy & Immunology will take aim at several of the world's most dangerous infectious diseases - tuberculosis, malaria and dengue virus -- in a five-year, $18.8 million federally-funded set of projects seeking to make new inroads toward vaccines against the disorders.

17 Dec 2009

PEPFAR decisions to be grounded in scientific evidence, Goosby says

U.S. Global AIDS Coordinator Eric Goosby "said future programmes to prevent HIV infection would be those supported by the best scientific evidence," reports the Financial Times. Goosby told the Financial Times in an interview: "I will always wrap myself in the science as the justification of decision-making. I will not factor in an ideological rationale."

17 Dec 2009

African AIDS vaccine conference addresses future trials in Africa, lower participation rates among women

During the Forum of the African AIDS Vaccine Program (AAVP) in Kampala, Uganda, on Wednesday, Alan Bernstein, the director of the Global HIV Vaccine Enterprise, discussed ongoing efforts to launch an experimental HIV vaccine trial - similar to the recent trial in Thailand - in Africa, the Daily Monitor reports.

17 Dec 2009

Hebrew University of Jerusalem granted $5M for research into visceral leishmaniasis in Ethiopia

17 Dec 2009

EPA approves BASF's Aseptrol S10 - Tab for H1N1 sanitization operations

BASF today announced that the Environmental Protection Agency (EPA) has approved the use of Aseptrol® S10 - Tab in H1N1 sanitization operations in institutional and industrial facilities, such as, schools, hospitals, government buildings, retail and restaurants, and recreational facilities. Aseptrol S10 - Tab is based on Chlorine dioxide (CIO2) release technology.

17 Dec 2009

AlphaRx, Venturepharm sign supply agreement for ARX1088's API

AlphaRx Inc. announced today that it has signed an agreement that provides long-term supply of the active pharmaceutical ingredient (API) for ARX1088, an orally active interferon inducer intended for the adjunctive treatment of Hepatitis in China and other emerging markets. Under the agreement, Venturepharm will be the primary supplier of AlphaRx's worldwide requirements for the compound.

17 Dec 2009

Anadys Pharmaceuticals reports positive 4-week results from its ANA598 Phase II study for HCV

Anadys Pharmaceuticals, Inc. today announced preliminary results from a planned interim analysis of data at four weeks for the first dose cohort, 200 mg bid, in an ongoing Phase II study of ANA598 in combination with pegylated interferon and ribavirin (SOC) in HCV patients.

17 Dec 2009

Three H1N1 influenza vaccination clinics scheduled to offer vaccines free of charge

2010 is just over two weeks away. Make a New Year's resolution for you and your family members and start the new year out right by getting your H1N1 influenza shot at one of the available clinics in southeast Michigan.

17 Dec 2009

Disease/Infection News

Many states still lack the 21st century technology capacity needed for disease surveillance

Government not held accountable for keeping nurses safe during SARS, Supreme Court denies appeal

Human protein may help prevent H1N1 infection

AHF praises California Assembly members' initiative to protect state’s AIDS drug program funding

Immuno Laboratories and TRPN sign agreement to reduce chronic illness

New WHO report shows considerable progress in malaria

Bill & Melinda Gates Foundation grants funds for visceral leishmaniasis research

Genetic variant associated with reduced risk of COPD

Flu-fighting proteins found in human cells stop flu virus, uncover scientists

Comprehensive approaches to understand the interaction of H1N1 strains with human cells

Hebrew University of Jerusalem receives $5 million grant from Bill & Melinda Gates Foundation

Update on Phase 2 clinical trial of oral interferon announced by Amarillo Biosciences

La Jolla Institute for Allergy & Immunology awarded $18.8M NIH grant for infectious diseases study

PEPFAR decisions to be grounded in scientific evidence, Goosby says

African AIDS vaccine conference addresses future trials in Africa, lower participation rates among women

Hebrew University of Jerusalem granted $5M for research into visceral leishmaniasis in Ethiopia

EPA approves BASF's Aseptrol S10 - Tab for H1N1 sanitization operations

AlphaRx, Venturepharm sign supply agreement for ARX1088's API

Anadys Pharmaceuticals reports positive 4-week results from its ANA598 Phase II study for HCV

Three H1N1 influenza vaccination clinics scheduled to offer vaccines free of charge

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News